Abnormal homocysteine metabolism in rheumatoid arthritis

Roubenoff, Ronenn; Dellaripa, Paul F.; Nadeau, Marie; Abad, Leslie W.; Muldoon, Bernadette A.; Selhub, Jacob; Rosenberg, Irwin H.

doi:10.1002/art.1780400418

Cited by 158 publications

(109 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Plasma Hcy concentrations also increase with age (Mijatovic et al, 1998). It has been reported that HHcy is related to diseases such as coronary heart disease (Cacciapuoti 2011;Frosst et al, 1995;Humphrey et al, 2008), kidney disease (Friedman et al, 2001), Alzheimer's disease (Moustafa et al, 2012), and rheumatoid arthritis (Roubenoff et al, 1997). Hcy also induces reactive oxygen species via HADPH activation, resulting in the production of several pro-inflammatory cytokines (Fujiki et al, 2012;Lawrence et al, 2002).…”

Section: Introductionmentioning

confidence: 99%

Plasma Homocysteine Concentrations in Dogs

Kakimoto¹,

Iwanaga²,

Kanouchi³

2014

IJVMR

View full text Add to dashboard Cite

Many human epidemiologic studies have reported associations between plasma homocysteine (Hcy) concentrations and cardiovascular disease, Alzheimer's disease, and osteoporosis. However, few studies have examined the relationship between Hcy and disease in dogs. In this study, we investigated the relationship between canine plasma Hcy concentrations and sex, age, breed, size; spay/neuter status, and disease. Plasma Hcy concentrations were related to sex and age, but the correlations were very weak. ShibaInu dogs and Labrador Retrievers had a higher risk of hyperhomocysteinemia than other breeds. We compared the plasma Hcy concentrations of healthy control dogs with those of dogs with heart, inflammatory, bone and joint, nervous system, neoplastic, skin, and kidney diseases. The mean plasma Hcy concentrations of dogs with cardiovascular, neoplasia, skin, and kidney diseases were significantly different from those of controls. However, multivariate logistic regression (parameters: Hcy concentration, age, sex, and spay/neuter status) revealed a significant relationship between only skin disease and plasma Hcy concentration. The odds ratio (per 1 μmol/l increase of Hcy) was 1.077 (95% confidence interval 1.00-1.158, p<0.05). Plasma Hcy concentrations significantly differ among dog breeds, and there is a relationship between high plasma Hcy concentration and skin disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Plasma Homocysteine Concentrations in Dogs

Kakimoto¹,

Iwanaga²,

Kanouchi³

2014

IJVMR

View full text Add to dashboard Cite

show abstract

“…Studies have shown that patients with RA had lower circulating levels of vitamin B 6 (that is, PLP) compared with healthy controls (Roubenoff et al, 1995(Roubenoff et al, , 1997Chiang et al, 2005a;Woolf and Manore, 2008). Patients with RA were under chronic inflammatory conditions, which may possibly increase the use and metabolic turnover of plasma PLP.…”

Section: Introductionmentioning

confidence: 99%

Vitamin B6 supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis

Wei

et al. 2010

Eur J Clin Nutr

103

View full text Add to dashboard Cite

Background/Objectives: The purpose of this study was to investigate whether vitamin B 6 supplementation had a beneficial effect on inflammatory and immune responses in patients with rheumatoid arthritis (RA). Subjects/Methods: This was a single-blind co-intervention study performed at the Division of Allergy, Immunology and Rheumatology of Chung Shan Medical University Hospital, Taiwan. Patients were diagnosed with RA according to the 1991 American College of Rheumatology criteria for RA. Patients were randomly allocated into two groups: control (5 mg/day folic acid only; n ¼ 15) or vitamin B 6 (5 mg/day folic acid plus 100 mg/day vitamin B 6 ; n ¼ 20) for 12 weeks. Plasma pyridoxal 5 0 -phosphate (PLP), serum folate, inflammatory parameters (that is, high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a)) and immune parameters (that is, white blood cell, total lymphocyte, T-cell (CD3), B-cell (CD19), T-helper cell (CD4), T-suppressor (CD8)) were measured on day 1 (week 0) and after 12 weeks (week 12) of the intervention. Results: In the group receiving vitamin B 6 , plasma IL-6 and TNF-a levels significantly decreased at week 12. There were no significant changes with respect to immune responses in both groups except for the percentage of total lymphocytes in the vitamin B 6 group when compared with week 0 and week 12. Plasma IL-6 level remained significantly inversely related to plasma PLP after adjusting for confounders (b ¼ À0.01, P ¼ 0.01). Conclusions: A large dose of vitamin B 6 supplementation (100 mg/day) suppressed pro-inflammatory cytokines (that is, IL-6 and TNF-a) in patients with RA.

show abstract

“…Certain medications used to treat IA and SLE may also contribute to the increased risk of CVD, including nonsteroidal anti-inflammatory drugs (NSAIDs) [20], COX-2 inhibitors [5,20], steroids [21,22], and anti-folate medications such as methotrexate [23,24].…”

Section: Introductionmentioning

confidence: 99%

Lack of cardiovascular risk assessment in inflammatory arthritis and systemic lupus erythematosus patients at a tertiary care center

2011

View full text Add to dashboard Cite

The purpose of this study is to evaluate cardiovascular risk assessment at a Canadian rheumatology center and describe the cardiovascular risk of inflammatory arthritis (IA) and systemic lupus erythematosus (SLE) patients using the Framingham risk score. A retrospective chart review of 504 patients attending nine rheumatology practices at the University of Alberta Hospital was performed. A pre-specified case report form detailed patient demographics, cardiac risk factors, variables for the Framingham 2008 score, disease activity, and medication use. In this group of 504 patients, 64 (12.7%) had SLE (male (M) to female (F) ratio=60:4) and 440 (87.3%) had an IA (M to F ratio=117:323). Of the SLE patients, 31 (48.4%) met four or more American College of Rheumatology (ACR) criteria, 33 (51.6%) had less than four ACR criteria. Of the IA patients, 156 (35.5%) were CCP positive and 257 (58.4%) were RF positive. Utilizing the chart data, retrospective Framingham risk scores were calculable for one (1.6%) SLE patient and three (0.68%) IA patients. The most common cardiac risk factors not documented in the medical records of both the SLE and IA patients included: (1) positive family history of MI, (2) diabetes, and (3) lipid status. The blood pressure was more frequently documented in the SLE patients (93.8%) compared to the IA patients (56.1%). While traditional cardiac risk factors only partially contribute to the increased cardiovascular risk in these patients, cardiovascular risk assessment was suboptimally performed amongst a large group of rheumatologists. A dedicated cardiovascular risk reduction clinic for inflammatory rheumatic diseases has been established at this site to fulfill this need and evaluate treatment strategies.

show abstract

Abnormal homocysteine metabolism in rheumatoid arthritis

Cited by 158 publications

References 25 publications

Plasma Homocysteine Concentrations in Dogs

Plasma Homocysteine Concentrations in Dogs

Vitamin B6 supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis

Lack of cardiovascular risk assessment in inflammatory arthritis and systemic lupus erythematosus patients at a tertiary care center

Contact Info

Product

Resources

About